Last Week Revance Therapeutics, Inc. (NASDAQ:RVNC) Ratings

April 17, 2018 - By Elizabeth Jones

Big Money Sentiment increased to 2.8 in Q4 2017. It has change of 1.80, from 2017Q3’s 1. The ratio improved due to Revance Therapeutics, Inc. positioning: 6 sold and 19 reduced. 31 funds bought positions and 39 increased positions. Investors holded 27.21 million in 2017Q3 but now own 31.34 million shares or 15.17% more.
Canada Pension Plan Invest Board accumulated 582,900 shs. Pnc Finance Services Grp Incorporated owns 48 shs or 0% of their US capital. The Illinois-based Citadel Advisors Ltd Liability Corp has invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Northern Corporation has 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 301,405 shs. Parametric Port Assocs Ltd Llc reported 72,855 shs or 0% of all its holdings. Proshare Advisors Llc invested 0% of its capital in Revance Therapeutics, Inc. (NASDAQ:RVNC). Franklin Res holds 3.39M shs or 0.06% of its capital. Nottingham Incorporated owns 11,312 shs. Goldman Sachs Gp Incorporated accumulated 26,546 shs. Alliancebernstein Limited Partnership reported 907,695 shs or 0.02% of all its holdings. Bnp Paribas Arbitrage Sa reported 4,849 shs stake. Bancshares Of America De holds 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC) or 9,483 shs. Renaissance Tech Limited Liability holds 87,956 shs. Metropolitan Life accumulated 7,537 shs or 0% of the stock. The New York-based Quinn Opportunity Ltd Liability Corporation has invested 0.05% in Revance Therapeutics, Inc. (NASDAQ:RVNC).

Revance Therapeutics, Inc. registered $2.77 million net activity with 1 buy and 6 insider sales since October 18, 2017. On Tuesday, March 13 the insider SILVERNAIL LAUREN P sold $892,412. On Friday, March 16 GARDNER PHYLLIS sold $168,045 worth of Revance Therapeutics, Inc. (NASDAQ:RVNC). On Friday, March 16 the insider Vickers Philip J. bought $98,393.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Ratings Coverage

In total 9 analysts cover Revance Therapeutics (NASDAQ:RVNC). “Buy” rating has 8, “Sell” are 0, while 1 are “Hold”. 89% are bullish. 19 are the (NASDAQ:RVNC)’s analyst reports since October 24, 2017 according to StockzIntelligence Inc. On Monday, November 27 the firm has “Buy” rating given by Barclays Capital. The company rating was maintained by Cantor Fitzgerald on Thursday, November 16. On Tuesday, October 24 Cantor Fitzgerald maintained Revance Therapeutics, Inc. (NASDAQ:RVNC) with “Buy” rating. On Wednesday, December 13 the company was maintained by Cantor Fitzgerald. The stock rating was maintained by Cowen & Co with “Buy” on Wednesday, January 17. On Thursday, April 12 Cantor Fitzgerald maintained the shares of RVNC in report with “Buy” rating. In Monday, March 5 report Goldman Sachs initiated the stock with “Buy” rating. On Thursday, November 16 the company was initiated by Mizuho. On Monday, March 26 the firm earned “Buy” rating by Needham. On Tuesday, January 9 the company was downgraded by Guggenheim. Listed here are Revance Therapeutics, Inc. (NASDAQ:RVNC) PTs and latest ratings.

12/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0000 Maintain
26/03/2018 Broker: Needham Rating: Buy New Target: $42.0000 Maintain
05/03/2018 Broker: Goldman Sachs Rating: Buy New Target: $60.0 Initiate
01/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $48.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0 Maintain
17/01/2018 Broker: Cowen & Co Rating: Buy New Target: $55.0 Maintain
09/01/2018 Broker: Guggenheim Old Rating: Buy New Rating: Neutral Old Target: $42 Downgrade
04/01/2018 Broker: Guggenheim Rating: Buy New Target: $44.0 Maintain
13/12/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0 Maintain
08/12/2017 Broker: SunTrust Rating: Buy New Target: $53.0 Maintain

Its shares touched $32.25 on during the last trading session after 1.53% change.Revance Therapeutics, Inc. has volume of 186,049 shares. Since April 17, 2017 RVNC has risen 51.24% and is uptrending. RVNC outperformed the S&P 500 by 39.69%.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications.The firm is worth $1.19 billion. The company's lead drug candidate is DaxibotulinumtoxinA for injection , which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.Last it reported negative earnings. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.